HRP20221465T1 - Farmaceutski sastav koji sadrži aprepitant i postupak za njegovu pripremu - Google Patents
Farmaceutski sastav koji sadrži aprepitant i postupak za njegovu pripremu Download PDFInfo
- Publication number
- HRP20221465T1 HRP20221465T1 HRP20221465TT HRP20221465T HRP20221465T1 HR P20221465 T1 HRP20221465 T1 HR P20221465T1 HR P20221465T T HRP20221465T T HR P20221465TT HR P20221465 T HRP20221465 T HR P20221465T HR P20221465 T1 HRP20221465 T1 HR P20221465T1
- Authority
- HR
- Croatia
- Prior art keywords
- aprepitant
- pharmaceutical composition
- diluent
- preparation
- lubricant
- Prior art date
Links
- ATALOFNDEOCMKK-OITMNORJSA-N aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 title claims 4
- 229960001372 aprepitant Drugs 0.000 title claims 4
- 239000008194 pharmaceutical composition Substances 0.000 title claims 4
- 238000000034 method Methods 0.000 title claims 2
- 238000002360 preparation method Methods 0.000 title claims 2
- 239000003085 diluting agent Substances 0.000 claims 4
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 claims 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 4
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- -1 acetate - polyethylene Chemical group 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229920000578 graft copolymer Polymers 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- 239000000314 lubricant Substances 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 229920002689 polyvinyl acetate Polymers 0.000 claims 2
- 239000011118 polyvinyl acetate Substances 0.000 claims 2
- 239000007962 solid dispersion Substances 0.000 claims 2
- 229920002554 vinyl polymer Polymers 0.000 claims 2
- 206010018691 Granuloma Diseases 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 239000007903 gelatin capsule Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (2)
1. Farmaceutski sastav koji obuhvaća amorfnu čvrstu disperziju aprepitanta s polivinil kaprolaktam - polivinil acetat - polietilen glikol graft kopolimerom, pri čemu je težinski omjer aprepitanta i nosača polivinil kaprolaktam - polivinil acetat - polietilen glikol graft kopolimera od 1:1 do 1: 4, koji farmaceutski sastav nadalje obuhvaća razrjeđivač, sredstvo za dezintegraciju, sredstvo za klizanje i lubrikant, a pri čemu je razrjeđivač laktoza.
2. Postupak za pripremu farmaceutskog sastava aprepitanta koji obuhvaća korake:
- miješanja granula amorfne čvrste disperzije kako je određeno u patentnom zahtjevu 1 s razrjeđivačem, sredstvom za razgradnju i sredstvom za klizanje, pri čemu je razrjeđivač laktoza dok se ne postigne potpuna homogenost;
- daljnjeg miješanja s lubrikantom i punjenja tvrdih želatinskih kapsula s dobivenim granuloma.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20150100035A GR20150100035A (el) | 2015-01-30 | 2015-01-30 | Φαρμακευτικο σκευασμα περιεχον απρεπιταντη και μεθοδος παρασκευης αυτου |
| GR20150100471A GR20150100471A (el) | 2015-10-27 | 2015-10-27 | Φαρμακευτικο σκευασμα περιεχον απρεπιταντη και μεθοδος παρασκευης αυτου |
| PCT/EP2016/000136 WO2016120013A1 (en) | 2015-01-30 | 2016-01-27 | Pharmaceutical composition comprising aprepitant and method for the preparation thereof |
| EP16703060.0A EP3250188B1 (en) | 2015-01-30 | 2016-01-27 | Pharmaceutical composition comprising aprepitant and method for the preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20221465T1 true HRP20221465T1 (hr) | 2023-01-20 |
Family
ID=55304961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20221465TT HRP20221465T1 (hr) | 2015-01-30 | 2016-01-27 | Farmaceutski sastav koji sadrži aprepitant i postupak za njegovu pripremu |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP3250188B1 (hr) |
| DK (1) | DK3250188T3 (hr) |
| ES (1) | ES2932626T3 (hr) |
| HR (1) | HRP20221465T1 (hr) |
| HU (1) | HUE060710T2 (hr) |
| LT (1) | LT3250188T (hr) |
| PL (1) | PL3250188T3 (hr) |
| PT (1) | PT3250188T (hr) |
| RS (1) | RS63790B1 (hr) |
| SI (1) | SI3250188T1 (hr) |
| WO (1) | WO2016120013A1 (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017194681A1 (en) * | 2016-05-12 | 2017-11-16 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Composition containing aprepitant |
| GR1009209B (el) * | 2016-11-17 | 2018-02-05 | Φαρματεν Αβεε | Φαρμακευτικο σκευασμα περιεχον εναν αντιεμετικο παραγοντα και μεθοδος για την παρασκευη αυτου |
| CN113350290A (zh) * | 2020-03-05 | 2021-09-07 | 科贝园(北京)医药科技有限公司 | 一种阿瑞匹坦固体分散组合物及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2034952A4 (en) * | 2006-06-16 | 2011-08-17 | Reddys Lab Ltd Dr | APREPITANT COMPOSITIONS |
| WO2008110534A1 (en) * | 2007-03-13 | 2008-09-18 | Sandoz Ag | Pharmaceutical compositions of poorly soluble drugs |
| EP1970535A1 (de) * | 2007-03-15 | 2008-09-17 | ABB Turbo Systems AG | Deckbandverbindung einer Turbinenschaufel |
| EP2813212A1 (en) * | 2013-06-10 | 2014-12-17 | Zentiva, a.s. | Drug formulation using API in nanofibers |
| EP2893919B1 (en) * | 2014-01-09 | 2017-07-12 | Sanofi | Formulation of aprepitant with enhanced solubility |
-
2016
- 2016-01-27 EP EP16703060.0A patent/EP3250188B1/en active Active
- 2016-01-27 HU HUE16703060A patent/HUE060710T2/hu unknown
- 2016-01-27 SI SI201631643T patent/SI3250188T1/sl unknown
- 2016-01-27 PT PT167030600T patent/PT3250188T/pt unknown
- 2016-01-27 LT LTEPPCT/EP2016/000136T patent/LT3250188T/lt unknown
- 2016-01-27 RS RS20221108A patent/RS63790B1/sr unknown
- 2016-01-27 PL PL16703060.0T patent/PL3250188T3/pl unknown
- 2016-01-27 ES ES16703060T patent/ES2932626T3/es active Active
- 2016-01-27 DK DK16703060.0T patent/DK3250188T3/da active
- 2016-01-27 HR HRP20221465TT patent/HRP20221465T1/hr unknown
- 2016-01-27 WO PCT/EP2016/000136 patent/WO2016120013A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| RS63790B1 (sr) | 2022-12-30 |
| PL3250188T3 (pl) | 2023-02-27 |
| DK3250188T3 (da) | 2022-12-19 |
| PT3250188T (pt) | 2022-12-14 |
| EP3250188B1 (en) | 2022-09-14 |
| EP3250188A1 (en) | 2017-12-06 |
| SI3250188T1 (sl) | 2023-01-31 |
| HUE060710T2 (hu) | 2023-04-28 |
| LT3250188T (lt) | 2022-12-27 |
| ES2932626T3 (es) | 2023-01-23 |
| WO2016120013A1 (en) | 2016-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20221465T1 (hr) | Farmaceutski sastav koji sadrži aprepitant i postupak za njegovu pripremu | |
| IL273300A (en) | High dose valbenazine formulation and related preparations, methods and kits | |
| BR112019024747A2 (pt) | formulações de dose fixa | |
| NZ606587A (en) | Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof | |
| EA201390913A1 (ru) | Новая фармацевтическая композиция | |
| WO2017218981A3 (en) | Compositions and methods for reducing ocular neovascularization | |
| CU24486B1 (es) | Dispersión sólida amorfa que comprende taxano, tabletas comprendiendo la misma y método para prepararla | |
| PH12019500778A1 (en) | Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone | |
| ZA201906541B (en) | Isoxazole derivatives as nuclear receptor agonists and uses thereof | |
| JP2016000763A5 (hr) | ||
| PH12015501168A1 (en) | Novel pharmaceutical composition | |
| WO2016063289A3 (en) | Pharmaceutical tablet compositions comprising rifaximin | |
| WO2012147101A3 (en) | Pharmaceutical compositions of raltegravir, methods of preparation and use thereof | |
| EP3564280A4 (en) | COPOLYMERS MADE FROM 1,3,7-OCTATRIENE AND STYRENE, HYDRID THEREOF, AND PROCESS FOR THE MANUFACTURING OF THE COPOLYMER | |
| EP3202404A8 (en) | Oral formulation of a-nor-5alpha androstane compound | |
| TW201613580A (en) | Ceritinib formulation | |
| EA201791523A1 (ru) | Пероральный фармацевтический состав, содержащий гранулы с замедленным высвобождением, содержащие тамсулозина гидрохлорид | |
| EP3442594C0 (en) | BLOCK COPOLYMER FOR OVERCOMING THE DRUG RESISTANCE OF TUMORS TO CHEMOTHERAPY, ITS POLYMER-DRUG CONJUGATE, PHARMACEUTICAL COMPOSITION THEREOF, METHOD FOR THE PRODUCTION AND USE THEREOF | |
| WO2016197042A8 (en) | Modified or targeted release formulations of linaclotide | |
| BR112018001199A2 (pt) | composições em pó de polímero redispersáveis com resistência ao impacto aperfeiçoada | |
| Holt et al. | In vitro design and drug delivery of combination dapivirine and contraceptive hormone ethylene vinyl acetate (EVA) vaginal ring prototypes | |
| WO2017064564A3 (en) | Therapeutic regimens for treating psoriatic arthritis with an anti-ccl20 antibody | |
| MX2018013274A (es) | Uso de alcoholes de azucar en composiciones de tibolona. | |
| HRP20210969T1 (hr) | Farmaceutski sastav koji sadrži darunavir i metoda za njegovu pripremu | |
| MX2015011101A (es) | Composiciones farmaceuticas de donepezilo que tienen un perfil de disolución in vitro o parámetros farmacocinéticos específicos. |